Salim Mujais News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Urovant Sciences, Inc : Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations

Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears

United statesSumitovant biopharmaSumitomo pharmaSalim mujaisMaya frutigerAlana darden powellJeffrey frankelInternational journal of clinical practiceAboutsumitovant biopharma ltdUrovant sciences gmbSeattle urology research centerSumitomo pharma co ltdCorporate communicationsUrovant sciencesSumitovant biopharma ltdHead of corporate communications

U S Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients

U S Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKenji yasukawaSalim mujaisAstellas pharma incDrug administrationPrnewswire astellas pharma incAstellas incNew drug applicationSenior vice presidentTherapeutic area headMedical specialtiesReal world evidenceTransplant recipientsOrphan drug designationPatient informationAstellas pharma

U S Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients

U S Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

U S Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients

Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel

Search jobs 12-Jul-2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) ASP3772 has also received FDA Breakthrough Therapy Designation CAMBRIDGE, Mass. & TOKYO (BUSINESS WIRE) Affinivax, Inc. ( Affinivax ) and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) platform technology, ASP3772 is designed to offer both B-cell (antibody) and T-cell immune protection against

United kingdomUnited statesStevenb bruggerSalim mujaisKathryn morrisYates networkAstellas pharma incEuropean congressDrug administrationMelinda gates foundationNational foundation for infectious diseaseAffinivax incClinical microbiologyInfectious diseasesAstellas pharmaMultiple antigen presenting system